Universal CAR-NK for relapsed/refractory B-cell lymphoma, 3/6 cases achieved CR

On April 25, U.
S.
time, Nkarta Therapeutic (later known as Nkarta) announced the latest clinical data on the company’s two CAR-NK pipelines, NKX101 (targeting NKG2D) and NKX019 (targeting CD19), in the treatment of hematological tumors
.

NKX019 is a CD19-targeting CAR-NK cell therapy from Nkarta and a "universal" CAR-NK cell therapy
.
Since CD19 is overexpressed in a variety of hematological tumors, NKX019 can be used to treat a variety of hematological malignancies
.

In a clinical trial evaluating NKX019 for the treatment of relapsed/refractory B-cell lymphoma , subjects (N=13) included patients with multiple types of lymphoma, 5 with large B-cell lymphoma (LBCL), 3 with follicular Lymphoma (FL), 1 marginal zone lymphoma (MZL), 3 mantle cell lymphoma (MCL), 3 B-cell acute lymphoblastic leukemia (B-ALL) at high dose (10x10 ⁸ CAR-NK cells , 3 infusions) group, of 6 evaluable patients: 5 achieved objective responses (ORR=83%) and 3 achieved complete responses (CR=50%), including one with diffuse large B-cell lymphoma patient and one mantle cell tumor patient
.

.

Likewise, no dose-limiting toxicities, as well as adverse events similar to the side effects of CAR-T
therapy, were found in this trial .